- Condition: Type 1 Diabetes
Interventions: Drug: Statin; Drug: Ace Inhibitor; Drug: Placebo; Drug: Combination therapy
Sponsors: Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Juvenile Diabetes Research Foundation; Diabetes UK; British Heart Foundation; Pfizer; The University of Western Australia; The Hospital for Sick Children; University of Oxford; St Thomas' Hospital, London
Recruiting - verified April 2012 - Condition: Major Depressive Disorder
Intervention: Drug: Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.
Sponsors: Baker IDI Heart and Diabetes Institute; Baker IDI Heart and Diabetes Institute; Alfred and Baker Medical Unit - Alfred Hospital; Monash Medical Centre - Southern Health; Ballarat Health Service Psychiatric Services
Not yet recruiting - verified March 2012 - Condition: Schizophrenia
Interventions: Drug: Moxonidine; Drug: Placebo; Drug: Moxonidine; Drug: Placebo
Sponsors: Baker IDI Heart and Diabetes Institute; Baker IDI Heart and Diabetes Institute; Alfred and Baker Medical Unit - Alfred Hospital; Monash Medical Centre - Southern Health; Ballarat Health Service Psychiatric Services
Not yet recruiting - verified April 2012 - Conditions: Diabetes; Stroke; Obesity
Intervention:
Sponsors: Children's & Women's Health Centre of British Columbia; Children's & Women's Health Centre of British Columbia
Recruiting - verified March 2012 - Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: biphasic insulin aspart 30; Drug: biphasic insulin aspart 30; Drug: sitagliptin; Drug: metformin
Sponsors: Novo Nordisk; Novo Nordisk
Not yet recruiting - verified May 2012 - Condition: Polycystic Ovary Syndrome
Interventions: Drug: Moxonidine; Drug: Placebo
Sponsors: Baker IDI Heart and Diabetes Institute; Baker IDI Heart and Diabetes Institute
Not yet recruiting - verified January 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Metformin; Drug: Placebo
Sponsors: University of Glasgow; University of Glasgow; NHS Greater Glasgow and Clyde; Juvenile Diabetes Research Foundation; Imperial College London; University of Wisconsin School of Medicine and Public Health; University of Dundee; Merck Serono S.A., Geneva; Itamar-Medical, Israel; University of Western Ontario, Canada; University of Melbourne; Steno Diabetes Center; Maastricht University Medical Center
Recruiting - verified January 2012 - Conditions: Major Depressive Disorder (MDD); Coronary Heart Disease (CHD); Cardiovascular Disease (CVD)
Interventions: Drug: Valdoxan (agomelatine); Drug: Lexapro (escitalopram)
Sponsors: Baker IDI Heart and Diabetes Institute; Baker IDI Heart and Diabetes Institute
Not yet recruiting - verified November 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: Insulin Glargine; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin; Drug: Comparator: Placebo; Biological: Insulin Glargine; Drug: Metformin
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Glargine; Drug: LY2605541; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Glargine; Drug: LY2605541
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: linagliptin; Drug: BI 10773 linagliptin FDC; Drug: BI 10773 linagliptin FDC; Drug: high dose BI 10773 placebo; Drug: high dose BI 10773 placebo; Drug: high dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: linagliptin; Drug: linagliptin; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: low dose FDC placebo; Drug: low dose FDC placebo; Drug: low dose FDC placebo; Drug: linagliptin placebo; Drug: linagliptin placebo; Drug: linagliptin placebo; Drug: BI 10773; Drug: BI 10773 high dose; Drug: BI 10773 low dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Obesity; Type 2 Diabetes
Intervention: Procedure: Hyperbaric Oxygen Treatment
Sponsors: University of Adelaide; University of Adelaide
Recruiting - verified March 2011 - Conditions: Abdominal Obesity; Hypertension
Interventions: Drug: Moxonidine; Drug: Irbesartan
Sponsors: Baker IDI Heart and Diabetes Institute; Baker IDI Heart and Diabetes Institute
Recruiting - verified February 2012 - Condition: HIV-1
Interventions: Drug: Maraviroc; Drug: Emtricitabine/tenofovir
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Conditions: Diabetes Mellitus; Macular Edema
Interventions: Biological: VEGF Trap-Eye (BAY86-5321); Biological: VEGF Trap-Eye (BAY86-5321); Procedure: Laser treatment
Sponsors: Bayer; Bayer; Regeneron Pharmaceuticals
Recruiting - verified May 2012 - Condition: Atherosclerosis
Interventions: Drug: Canakinumab; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Type 1 Diabetes Mellitus; Retinopathy; Diabetic Nephropathy
Interventions: Drug: Fenofibrate; Drug: Inert lactose placebo
Sponsors: University of Sydney; University of Sydney; Abbott; University of Melbourne; St Vincents Hospital, Melbourne; Melbourne Health; Royal Prince Alfred Hospital, Sydney, Australia
Not yet recruiting - verified March 2011 - Condition: Peripheral Arterial Disease
Interventions: Drug: Niacin/Laropiprant combination; Drug: Sugar pill
Sponsors: Bayside Health; Bayside Health; National Health and Medical Research Council, Australia
Recruiting - verified July 2011 - Condition: Gestational Diabetes Mellitus
Intervention: Behavioral: Supervised home-based exercise
Sponsors: The University of Western Australia; The University of Western Australia; King Edward Memorial Hospital
Recruiting - verified March 2012 - Conditions: Acute Myocardial Infarction; Coronary Artery Disease; Oxygen
Interventions: Other: Withholding oxygen in uncomplicated patients with STEMI; Other: Oxygen
Sponsors: Bayside Health; Bayside Health; Ambulance Victoria; Monash University - Department of epidemiology and preventitive medicine; Baker IDI Heart and Diabetes Institute; FALCK Foundation
Recruiting - verified October 2011 - Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Bardoxolone Methyl: 20 mg
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Condition: Gastroparesis
Interventions: Drug: GSK962040 (5 mg tablet); Drug: GSK962040 (25 mg tablet); Drug: GSK962040 (125 mg tablet); Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepride placebo; Drug: linagliptin placebo; Drug: linagliptin; Drug: glimepiride
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Metabolic Syndrome; Diabetes
Intervention: Dietary Supplement: high fat overfeeding
Sponsors: University of Adelaide; University of Adelaide
Recruiting - verified October 2010 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Conditions: Diabetic Retinopathy; Macular Edema
Interventions: Drug: bevacizumab; Drug: dexamethasone
Sponsors: University of Sydney; University of Sydney; National Health and Medical Research Council, Australia
Recruiting - verified February 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Exenatide Once Weekly; Drug: Placebo
Sponsors: Amylin Pharmaceuticals, Inc.; Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified December 2011 - Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 high dose; Drug: Placebo BI 10773 high dose; Drug: BI 10773 low dose; Drug: BI 10773 high dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Diabetic Kidney Disease; Diabetic Nephropathy; Diabetic Glomerulosclerosis
Interventions: Drug: LY2382770; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Liver Transplant Recipient
Interventions: Drug: Tacrolimus; Drug: Tacrolimus + everolimus; Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Cystic Fibrosis; Diabetes
Intervention: Drug: Once-daily insulin detemir
Sponsors: Sydney Children's Hospital; Sydney Children's Hospital; The Children's Hospital at Westmead; John Hunter Children's Hospital
Recruiting - verified July 2011 - Condition: Diabetic Nephropathies
Interventions: Drug: Moxonidine; Drug: Placebo
Sponsors: Baker IDI Heart and Diabetes Institute; Baker IDI Heart and Diabetes Institute
Recruiting - verified March 2010 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified March 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: pioglitazone
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified October 2011 - Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012 - Condition: Acute Kidney Dysfunction
Interventions: Drug: Atorvastatin; Drug: Placebo
Sponsors: Austin Health; Austin Health
Recruiting - verified August 2009 - Condition: Heart Failure
Intervention: Other: NGAL kit
Sponsors: The Alfred; The Alfred; Biosite
Recruiting - verified February 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin phosphate; Drug: Placebo
Sponsors: Merck; Merck; Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Oral Insulin
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID); National Center for Research Resources (NCRR); American Diabetes Association; Juvenile Diabetes Research Foundation
Recruiting - verified February 2012 - Condition: Coronary Artery Disease
Intervention:
Sponsors: Monash University; Monash University; Royal Brompton & Harefield NHS Foundation Trust; IM Medical Ltd, Melbourne
Recruiting - verified March 2012 - Condition: Diabetes Mellitus, Type 1
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified March 2012 - Conditions: Stroke; Myocardial Infarction; Diabetes
Interventions: Drug: pioglitazone; Drug: placebo
Sponsors: Yale University; Yale University; National Institute of Neurological Disorders and Stroke (NINDS); Takeda Pharmaceuticals North America, Inc.
Recruiting - verified August 2011


